Clinical trials: cTACE
Hypervascular Tumors
Instylla HES Hypervascular Tumor Pivotal Study
To determine whether Instylla HES has the ability to effectively embolize targeted arterial segments of hypervascular tumors as well as (i.e., is non-inferior to) standard of care (SOC) transarterial embolization/conventional…
- Trial name
- NCT04523350
- Testing
- Instylla HES, TAE or cTACE
- Where
- 15 sites in United States, Canada
- Volunteers
- 150 people
- Sponsor
- Instylla, Inc.
Unresectable Intrahepatic Cholangiocarcinoma
A Trial of Systemic Chemotherapy in Combination With Conventional Transarterial Chemoembolization in Patients With Advanced Intra-Hepatic Cholangiocarcinoma
The study will be a single-center, single-arm, Phase II study of gemcitabine and cisplatin in combination with conventional trans-arterial chemoembolization therapy in adult patients with advanced ICC.
- Trial name
- NCT02994251
- Testing
- gemcitabine, Cisplatin, Conventional TACE (transarterial chemoembolization) with Doxorubicin/Mitomycin-C
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Yale University
Liver Cancer
Pharmacokinetics of Doxorubicin in cTACE of Liver Cancer
Patients with primary and secondary liver cancer may participate in this study. The purpose is to perform an analysis of the effects of doxorubicin and its metabolite doxorubicinol on the body (doxorubicin pharmacokinetics )…
- Trial name
- NCT02753881
- Testing
- whole liver lobe cTACE doxorubicin, superselective cTACE doxorubicin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Yale University
Unresectable Intrahepatic Cholangiocarcinoma
Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma
The purposed of this research is to study the safety and clinical activity of the combination of durvalumab and a CSF-1R inhibitor (SNDX-6352) in people with Intrahepatic Cholangiocarcinoma.
- Trial name
- NCT04301778
- Testing
- Durvalumab, SNDX-6352
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins